Junji Furuse
Active 2002–2025
- 142
- Papers
- 23,290
- Citations
- 74
- h-index
- 136
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine81.4%
- Biochemistry, Genetics and Molecular Biology14.1%
- Immunology and Microbiology2.6%
- Engineering0.4%
- Neuroscience0.3%
- Materials Science0.2%
- Other1%
Topics
- Hepatocellular Carcinoma Treatment and Prognosis10.9%
- Cholangiocarcinoma and Gallbladder Cancer Studies9%
- Cancer Immunotherapy and Biomarkers6.9%
- Pancreatic and Hepatic Oncology Research6.9%
- Gallbladder and Bile Duct Disorders3.3%
- Cancer Mechanisms and Therapy2.8%
- Other60.2%
Coauthors
- Masafumi Ikeda59
- Takuji Okusaka56
- Makoto Ueno43
- Chigusa Morizane36
- Masatoshi Kudo30
- Hiroshi Ishii27
- Naohiro Okano20
- Nobumasa Mizuno17
- Masato Ozaka16
- Robin Kate Kelley15
- Yoshito Komatsu13
- Masayuki Furukawa12
- Satoshi Kobayashi12
- Tatsuya Ioka12
- Ghassan K. Abou‐Alfa11
- Juan W. Valle11
- Kohei Nakachi11
- Bruno Sangro10
- John Bridgewater10
- Yasushi Kojima10
- Stephen L. Chan9
- Susumu Hijioka9
- Tatsuya Yamashita9
- Yasuyuki Kawamoto9
All papers
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Authors: Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko, Thomas Yau, Sérgio Jobim Azevedo, Marı́a Varela, Ann‐Lii Cheng, Shukui Qin, Peter R. Galle, Sajid Ali, Michelle Marcovitz, Mallory Makowsky, Philip He, John F. Kurland, Alejandra Negro, Bruno Sangro - NEJM Evidence 2022 cited by 1,432
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Authors: Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K Abou-Alfa, Anthony B El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro - The Lancet Oncology 2021 cited by 1,097
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assénat, Eric Assenat, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025
- Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Authors: Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin Kate Kelley, Philippe A. Cassier, Heinz‐Josef Klümpen, Heung-Moon Chang, Li‐Tzong Chen, Josep Tabernero, Do‐Youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu, Kunihiro Masuda, Daniel H. Ahn, Robert S. Epstein, Abdel‐Baset Halim, Yao Fu, Tehseen Salimi, Volker Wacheck, Yaohua He, Mei Liu, Karim A. Benhadji, John Bridgewater - New England Journal of Medicine 2023 cited by 541
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Authors: Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min‐Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat Shacham‐Shmueli, Xinqun Chen, Carlos Mayo, Soonmo Peter Kang, Atsushi Ohtsu, Charles S. Fuchs, Guillermo Lerzo, Juan Manuel O’Connor, Guillermo Ariel Mendez, James Lynam, Niall C. Tebbutt, Mark Wong, Andrew Strickland, Christos S. Karapetis, David Goldstein, Paul L. Vasey, Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay and 58 more - The Lancet 2018 cited by 1,316
- Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Authors: Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Kohichiroh Yasui, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Osamu Yokosuka, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai - Gut 2019 cited by 723
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Authors: Bruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S. Finn, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Thomas Yau, Junji Furuse, Joong‐Won Park, Zachary Boyd, Hao Tang, Yun Shen, Marina Tschaika, Jaclyn Neely, Anthony B. El-Khoueiry - Journal of Hepatology 2020 cited by 421
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Authors: Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo, George Lau, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Philip He, Alejandra Negro, Bruno Sangro - Journal of Clinical Oncology 2022 cited by 400
- Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Authors: Yoshiaki Nakamura, Hiroya Taniguchi, Masafumi Ikeda, Hideaki Bando, Ken Kato, Chigusa Morizane, Taito Esaki, Yoshito Komatsu, Yasuyuki Kawamoto, Naoki Takahashi, Makoto Ueno, Yoshinori Kagawa, Tomohiro Nishina, Takeshi Kato, Yoshiyuki Yamamoto, Junji Furuse, Tadamichi Denda, Hisato Kawakami, Eiji Oki, Takako Eguchi Nakajima, Naohiro Nishida, Kensei Yamaguchi, Hisateru Yasui, Masahiro Goto, Nobuhisa Matsuhashi, Koushiro Ohtsubo, Kentaro Yamazaki, Akihito Tsuji, Wataru Okamoto, Katsuya Tsuchihara, Takeharu Yamanaka, Miki Izumi, Yasutoshi Sakamoto, Hiroko Ichiki, Masayuki Hata, Riu Yamashita, Atsushi Ohtsu, Justin I. Odegaard, Takayuki Yoshino - Nature Medicine 2020 cited by 366
- Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
Authors: Kiyoshi Hasegawa, Nobuyuki Takemura, Tatsuya Yamashita, Takeyuki Watadani, Masaki Kaibori, Shoji Kubo, Mitsuo Shimada, Hiroaki Nagano, Etsuro Hatano, Hiroshi Aikata, Hiroko Iijima, Kazuomi Ueshima, Kazuyoshi Ohkawa, Takuya Genda, Kaoru Tsuchiya, Takuji Torimura, Masafumi Ikeda, Junji Furuse, Masaaki Akahane, Satoshi Kobayashi, Hideyuki Sakurai, Atsuya Takeda, Takamichi Murakami, Utaroh Motosugi, Yutaka Matsuyama, Masatoshi Kudo, Ryosuke Tateishi - Hepatology Research 2023 cited by 269
- Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Authors: Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, Shogo Nomura, Hiroshi Katayama, Tomoko Kataoka, Akiko Todaka, Hiroaki Yanagimoto, Soichiro Morinaga, Shogo Kobayashi, Kazuaki Shimada, Yu Takahashi, Toshio Nakagohri, Kunihito Gotoh, Ken Kamata, Yasuhiro Shimizu, Makoto Ueno, Hiroshi Ishii, Takuji Okusaka, Junji Furuse, Keiya Okamura, Yasuyuki Kawamoto, Akio Katanuma, Michiaki Unno, Hirofumi Shirakawa, Hironori Yamaguchi, Amane Takahashi, Masafumi Ikeda, Hiroo Yanagibashi, Naoya Kato, Takuji Okusaka, Yoshihiro Sakamoto, Yasushi Kojima, Ryota Higuchi, Naoki Sasahira, Keiji Sano, Toshio Nakagohri, Yu Sunakawa, Soichiro Morinaga, Yusuke Kumamoto, Kazuya Sugimori, Tatsuya Nomura, Kazuto Shibuya, Isamu Makino, Kentaro Yamazaki, Nobumasa Mizuno, Ken Kamata, Hiroshi Wada, Kunihito Gotoh, Mitsugu Sekimoto, Tetsuo Ajiki, Ikuo Nakamura, Ikuya Miki, Hiroaki Nagano, Koji Ohta, Takehiro Okabayashi, Masayuki Furukawa, Nao Fujimori - The Lancet 2023 cited by 232
- Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Authors: Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip J. Johnson, Yasuaki Arai, on behalf of the TACTICS Study Group - Liver Cancer 2022 cited by 128
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
Authors: Takuji Okusaka, Kohei Nakachi, Akira Fukutomi, Nobumasa Mizuno, S. Ohkawa, A Funakoshi, Masato Nagino, Satoshi Kondo, Soshi Nagaoka, Jumpei Funai, Minori Koshiji, Yoshihiro Nambu, Junji Furuse, Masaru Miyazaki, Y Nimura - British Journal of Cancer 2010 cited by 752
- Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
Authors: Fuyuhiko Motoi, Tomoo Kosuge, Hideki Ueno, Hiroki Yamaue, Sohei Satoi, Masayuki Sho, Goro Honda, Ippei Matsumoto, Keita Wada, Junji Furuse, Yutaka Matsuyama, Michiaki Unno, Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP) - Japanese Journal of Clinical Oncology 2018 cited by 534
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Authors: Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Hiroshi Katayama, Makoto Ueno, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akira Fukutomi, Hiroki Hara, Nobumasa Mizuno, Hiroaki Yanagimoto, Keita Wada, Kazutoshi Tobimatsu, Kei Yane, Shoji Nakamori, Hiroyuki Yamaguchi, Akinori Asagi, Seigo Yukisawa, Yasushi Kojima, Ken Kawabe, Yasuyuki Kawamoto, Rie Sugimoto, Tomohisa Iwai, Kazuyoshi Nakamura, Hiroyoshi Miyakawa, Tatsuya Yamashita, A. Hosokawa, Tatsuya Ioka, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse - Annals of Oncology 2019 cited by 334
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
Authors: Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, Nobuyoshi Hiraoka, Hiroshi Yoshida, Aya Kuchiba, Ryo Sadachi, Kenichi Nakamura, Naoko Matsui, Yoshiaki Nakamura, Wataru Okamoto, Takayuki Yoshino, Takuji Okusaka - Journal of Clinical Oncology 2022 cited by 107
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Authors: Makoto Ueno, Masafumi Ikeda, Chigusa Morizane, Satoshi Kobayashi, Izumi Ohno, Shunsuke Kondo, Naohiro Okano, Keisuke Kimura, Suguru Asada, Yoshinobu Namba, Takuji Okusaka, Junji Furuse - The Lancet. Gastroenterology & hepatology 2019 cited by 332
- A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Authors: Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai - Liver Cancer 2023 cited by 94
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
Authors: Tanios S Bekaii-Saab, Juan W. Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa Macarulla, John Bridgewater, Harpreet Wasan, Mitesh J. Borad, Ghassan K. Abou‐Alfa, Ping Jiang, Christine Lihou, Hui‐Ling Zhen, Ekaterine Asatiani, Luis Féliz, Arndt Vogel - Future Oncology 2020 cited by 165
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
Authors: Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao‐Ping Chen, Lucy Dagher, Junji Furuse, Jean-François H. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou, Tadatoshi Takayama, Arun J. Sanyal, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni - Journal of Hepatology 2016 cited by 385
- The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Authors: Alan P. Venook, Christos N. Papandreou, Junji Furuse, Laura Ladrón de Guevara - The Oncologist 2010 cited by 977
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
Authors: Masatoshi Kudo, Kazuho Imanaka, Nobuyuki Chida, Kohei Nakachi, Won Young Tak, Tadatoshi Takayama, Jung‐Hwan Yoon, Takeshi Hori, Hiromitsu Kumada, Norio Hayashi, Shuichi Kaneko, Hirohito Tsubouchi, Dong Jin Suh, Junji Furuse, Takuji Okusaka, Katsuaki Tanaka, Osamu Matsui, Michihiko Wada, Iku Yamaguchi, Toshio Ohya, Gerold Meinhardt, Kiwamu Okita - European Journal of Cancer 2011 cited by 573
- Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Authors: Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, Takuji Okusaka, Hiroshi Ishii, Junji Furuse - Japanese Journal of Clinical Oncology 2017 cited by 274
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Authors: Andrew X. Zhu, Masatoshi Kudo, Eric Assénat, Stéphane Cattan, Yoon‐Koo Kang, Ho Yeong Lim, Ronnie T.P. Poon, Jean-Frédéric Blanc, Arndt Vogel, Chao‐Long Chen, Étienne Dorval, Markus Peck‐Radosavljevic, Armando Santoro, Bruno Daniele, Junji Furuse, Annette Jappe, Kevin Perraud, Oezlem Anak, Dalila Sellami, Li‐Tzong Chen - JAMA 2014 cited by 569
